Effect of linagliptin on glycemic control in Chinese patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus: A randomized controlled trial

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 2678-2684

  Wu, Wenjun ^a   Li, Ying ^a   Chen, Xiong ^a   Lin, Dini ^a   Xiang, Songying ^a   Shen, Feixia ^a   Gu, Xuemei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Patients; Randomized controlled Trial; Type 2

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BODY MASS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HIP CIRCUMFERENCE; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; WAIST CIRCUMFERENCE; ADULT; ANALYSIS; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; TIME FACTOR;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIFE STYLE; LINAGLIPTIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TIME FACTORS;

EID: 84941202359     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894026     Document Type: Article

References (24)

1. Guariguata L, Whiting DR, Hambleton I et al: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract, 2014; 103: 137–49
2. Yang W, Lu J, Weng J et al: Prevalence of diabetes among men and women in China. N Engl J Med, 2010; 362: 1090–101
3. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA, 1999; 281: 2005–12
4. Hauber AB, Mohamed AF, Johnson FR, Falvey H: Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucoselowering agents. Diabet Med, 2009; 26: 416–24
5. Hung AM, Roumie CL, Greevy RA et al: Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int, 2012; 81: 698–706
6. LeRoith D: TSI neLWW, 2000. In: OJM, (ed.), Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000
7. Gallwitz B: Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy. Clin Med Insights Endocrinol Diabetes, 2012; 5: 1–11
8. Gallwitz B, Rosenstock J, Rauch T et al: 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet, 2012; 380: 475–83
9. Barnett AH, Patel S, Harper R et al: Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week activecontrolled extension. Diabetes Obes Metab, 2012; 14: 1145–54
10. Kawamori R, Inagaki N, Araki E et al: Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab, 2012; 14: 348–57
11. Bajaj M, Gilman R, Patel S et al: Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med, 2014; 31: 1505–14
12. Wang W, Yang J, Yang G et al: Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial. J Diabetes, 2015 [Epub ahead of print]
13. Zeng Z, Yang JK, Tong N et al: Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin, 2013; 29: 921–29
14. Villegas R, Liu S, Gao YT et al: Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. Arch Intern Med, 2007; 167: 2310–16
15. Doupis J, Veves A: DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther, 2008; 25: 627–43
16. Matthews DR, Hosker JP, Rudenski AS et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412–19
17. Seaquist ER, Anderson J, Childs B et al: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care, 2013; 36: 1384–95
18. Mohan V, Yang W, Son HY et al: Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract, 2009; 83: 106–16
19. Del Prato S, Barnett AH, Huisman H et al: Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab, 2011; 13: 258–67
20. Rosenstock J, Aguilar-Salinas C, Klein E et al: Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 2009; 25: 2401–11
21. Modesti PA: Season, temperature and blood pressure: a complex interaction. Eur J Intern Med, 2013; 24: 604–7
22. Mistry GC, Maes AL, Lasseter KC et al: Effect of sitagliptin, a dipeptidyl peptidase- 4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol, 2008; 48: 592–98
23. Ogawa S, Ishiki M, Nako K et al: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med, 2011; 223: 133–35
24. Monami M, Dicembrini I, Mannucci E: Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab, 2014; 16: 48–56